Blog - Page 3191 of 5756

ThursdayNov 15, 2012 6:32 pm

Market Leader, Inc. (LEDR) Partnership with Keller Williams Realty, Inc. Fosters Significant Productivity Increases with eEdge Platform

Market Leader announced this week that it has made a substantial contribution to the impressive productivity gains displayed by Keller Williams Realty during their partnership over the last twelve months. Keller Williams, the second largest real estate franchise in the United States, launched eEdge last year. eEdge is the first fully integrated front-end and back-end platform in the real estate industry to give customers the ability to manage their businesses with a single, seamless solution. The platform, powered by Market Leader and currently available to more than 80,000 Keller Williams associates, features custom websites, lead generation, contact management, and marketing…

ThursdayNov 15, 2012 6:31 pm

NeoStem, Inc. (NBS) Ranked #1 in Tri-State Region

NeoStem today announced that the company has been ranked #1 regionally in the New York Tri-State region and #7 nationally on Deloitte’s 2012 Technology Fast 500. The ranking is a list of the 500 fastest growing technology, media, telecommunications, life sciences, and clean technology companies in North America. Based in New York, NeoStem is focused on developing cell therapy products, technologies, and procedures. Through its subsidiary Progenitor Cell Therapy, the company is collaborating with Becton-Dickinson in the early clinical exploration of a T-cell therapy for autoimmune conditions. NeoStem’s most clinically advanced therapeutic product candidate, AMR-001, is being developed at Amorcyte,…

ThursdayNov 15, 2012 6:29 pm

Boston Therapeutics, Inc. (BTHE) Reports Financial Results, Shares Excitement for Upcoming Year

2012 Boston Therapeutics, a developer of complex carbohydrate therapeutics designed to treat diabetes and inflammatory diseases, yesterday reported its financial results for the three and nine months ended September 30, 2012. “We made good progress this year laying the foundation to commercialize our complex carbohydrate diabetes compounds,” stated David Platt, Ph.D., Chairman and Chief Executive Officer of Boston Therapeutics. “The recent addition of Jonathan Rome as our Chief Operating Officer will help accelerate the commercialization of SUGARDOWN® and the filing of an Abbreviated New Drug Application for BTI-7, a new, chewable dosage form of the diabetes drug metformin hydrochloride. We…

ThursdayNov 15, 2012 6:29 pm

Alimera Sciences, Inc. (ALIM) Announces New European Management Team

Alimera Sciences, a biopharmaceutical company that specializes in the research, development, and commercialization of prescription ophthalmic pharmaceuticals, announced that it has appointed the management team that will oversee European commercialization of its lead product, ILUVIEN®. Philip Ashman, Ph.D., has been appointed senior vice president and European managing director, while Eric Teo, MBBS, will serve as vice president and European medical director with Anne-Marie swift serving as vice president and European marketing director. Dan Myers, president and chief executive officer, Alimera, said, “I am delighted to welcome these talented individuals to Alimera. We believe their broad pharmaceutical experience, and knowledge of…

ThursdayNov 15, 2012 6:27 pm

Liberator, Inc. (LUVU) Announces Strong Financial Results for First Quarter Fiscal 2013

Liberator, a leading producer of sexual health and wellness products, recently reported their Q1 2013 financials for the period ended September 30, 2012. The Georgia-based company recorded revenue of $3.2 million, up 9% from the same quarter in fiscal 2012. They reported gross profit from continuing operations of $1.0 million, up from the $.9 million reported for the same period a year earlier. They reported income from continuing operations of approximately $91,000, compared to a net loss of approximately $52,000 in Q1 fiscal 2012. And they reported net income of approximately $6,000, compared to a net loss from continuing operations…

ThursdayNov 15, 2012 6:27 pm

GlobalWise Investments, Inc. (GWIV) Reports Strong Financial Results with Double-Digit Growth

GlobalWise Investments and its wholly owned subsidiary Intellinetics, an enterprise content management (“ECM”) software development, sales, and marketing company, just announced financial results for the third quarter and nine months ended September 30, 2012. Financial Highlights for the quarter include: o Total revenue increased by 15% to $711,737 compared to $617,026 in the year-ago third quarter; o Gross profit improved to $484,205, a 23% increase over the year-ago third quarter of $395,104; o Gross profit margin increased to 68% compared to 64% in the year-ago third quarter; o Operating expenses, excluding non-recurring and non-cash expenses totaling $206,800, increased to $682,976…

WednesdayNov 14, 2012 6:39 pm

Nanosphere, Inc. (NSPH) Receives FDA Clearance to Market the Verigene CYP2C19 Test

Nanosphere, a leading provider of advanced molecular diagnostics systems, announced that the U.S. Food and Drug Administration has granted 510(k) clearance, permitting the marketing of the company’s CYP2C19 Nucleic Acid Test on the automated sample-to-result Verigene System. The Verigene CYP2C19 Test is indicated as an aid to help clinicians determine therapeutic strategy for drugs metabolized by the CYP450 2C19 genetic pathway. In less than 2.5 hours, the Verigene CYP2C19 Test identifies the CYP2C19 *2, *3, and *17 variations, if present, directly from a patient’s whole blood sample. The test gives physicians the crucial information they need to treat patients quickly…

WednesdayNov 14, 2012 6:38 pm

Jonathan B. Rome Named COO of Boston Therapeutics, Inc. (BTHE)

Yesterday, Boston Therapeutics announced that Mr. Jonathan B. Rome has been named as its Chief Operating Officer. David Platt, Ph.D., Boston’s CEO, remarked, “Jonathan Rome has more than 30 years’ experience and success in the sales, marketing and distribution of pharmaceutical products and developing collaborations around the world. Jonathan is an excellent choice to commercialize SUGARDOWN® and to lead the filing of an ANDA to market BTI-7.” Mr. Rome was the Founder, President, and CEO of ThePharmaNetwork, LLC, which was focused on pharmaceutical portfolio development, licensing, sales, marketing, and distribution of pharmaceuticals and APIs as well as sales, marketing, and…

WednesdayNov 14, 2012 6:38 pm

Quaterra Resources, Inc. (QMM) Shows Solid Intervals Like 2.62 feet at 54.5 Ounces Per Ton Silver in Newly Discovered Zone at Nieves Project

Quaterra Resources today reported excellent evidence of their model for the Nieves silver property in northern Zacatecas, Mexico, as assay results on eight core holes drilled (just over 10k feet total) from August through October come in via the company and its 50% JV partner, Blackberry Ventures I, LLC, offering positive correlation that there is indeed a sizeable, high-level hydrothermal system, potentially stretching well out beyond extant discoveries. Project Manager at the Nieves, Hector Fernandez, noted the long running analytical modality at QMM which projected the vein system’s extents considerably further to the west and how the intersection of 2.62…

WednesdayNov 14, 2012 6:37 pm

Consorteum Holdings, Inc. (CSRH) Files Form 10-K Report with SEC

Consorteum Holdings just announced that it filed its Report on Form 10-K for the fiscal year ended June 30, 2012, with the Securities and Exchange Commission and resumed its status as an issuer quoted on the OTCQB. The company also told investors that some of its affiliates, as well as Consorteum, entered into a settlement agreement with its former CEO and Chairman of its Board of Directors. The settlement agreement was filed as an exhibit to the Form 10-K Report. Subsequent to the execution of this agreement, Consorteum and its former CEO executed and delivered to each other general releases.…

Site Search

Company Search